Table 1. Correlation between PIEZO2 expression and clinicopathological characteristics in TCGA breast cancer.
| Features | Breast cancer | |||
| PIEZ02 | ||||
| low/high expression case (n) | aP value | |||
| Age at diagnosis | Cases | |||
| <=51 | 367 | 283/84 | 0.6101 | |
| >51 | 729 | 572/157 | ||
| Estrogen receptor status | ||||
| Positive | 806 | 596/210 | < 0.0001 | |
| Negative | 240 | 224/16 | ||
| NA | 50 | 35/15 | ||
| Progesterone receptor status | ||||
| Positive | 698 | 513/185 | < 0.0001 | |
| Negative | 345 | 304/41 | ||
| NA | 53 | 38/15 | ||
| Her2 receptor status | ||||
| Positive | 161 | 147/14 | < 0.0001 | |
| Negative | 564 | 425/139 | ||
| NA | 371 | 283/88 | ||
| T stage | ||||
| T1 | 280 | 193/87 | < 0.0001 | |
| T2/T3/T4 | 813 | 660/153 | ||
| TX | 3 | 2/1 | ||
| N stage | ||||
| N0/N1 | 880 | 675/205 | 0.0221 | |
| N2/N3 | 196 | 165/31 | ||
| NX | 20 | 15/5 | ||
| M stage | ||||
| M0 | 910 | 711/199 | 0.8316 | |
| M1 | 21 | 16/5 | ||
| MX | 165 | 128/37 | ||
| Pathologic stage | ||||
| I | 182 | 125/57 | 0.0010 | |
| II/III/IV | 891 | 711/180 | ||
| NA | 23 | 19/4 | ||
aFor analysis of relationship between PIEZO2 levels and various clinicopathological features, Pearson’s Chi-Square test was employed. If the expected count of variable was less than 5 and more than 1, Yates’ continuity corrected Chi-Square test was used. When the expected count of variable was less than 1, Fisher’s exact test was utilized.
The significant P value is marked with Bold type. NA=Not Applicable.